A.O.U. Federico Ii Di Napoli
Welcome,         Profile    Billing    Logout  
 8 Trials 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Placido, Sabino De
EMBER-3, NCT04975308 / 2021-000079-35: A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer

Active, not recruiting
3
866
Europe, Japan, US, RoW
Imlunestrant, LY3484356, Exemestane, Fulvestrant, Abemaciclib, LY2835219
Eli Lilly and Company, Eli Lilly and Company
Breast Neoplasms, Neoplasm Metastasis
06/24
08/27
HER2CLIMB-05, NCT05132582 / 2021-002491-39: A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer

Active, not recruiting
3
654
Europe, Canada, Japan, US, RoW
Tucatinib, TUKYSA, ONT-380, ARRY-380, Trastuzumab, Herceptin, Herceptin Hylecta, Pertuzumab, Perjeta, Combination product: Trastuzumab + Pertuzumab, Phesgo, Placebo
Seagen Inc., Merck Sharp & Dohme LLC
HER2 Positive Breast Cancer
05/25
10/27
EMBER-4, NCT05514054: A Study of Imlunestrant Versus Standard Endocrine Therapy in Participants With Early Breast Cancer

Recruiting
3
6000
Europe, Canada, Japan, US, RoW
Imlunestrant, LY3484356, Tamoxifen, Anastrozole, Letrozole, Exemestane
Eli Lilly and Company
Breast Neoplasms
10/27
03/32
NCT05266937: Atezolizumab Plus CArboplatin Plus Nab-paclitaxel

Active, not recruiting
2
49
Europe
Atezolizumab,Paclitaxel, Carboplatin
Consorzio Oncotech
Metastatic Breast Cancer, Triple Negative Breast Cancer, PD-L1 Gene Mutation
07/24
07/24
BREAKFAST-2, NCT05763992: Targeting Triple Negative BREAst Cancer Metabolism With a Combination of Chemoimmunotherapy and a FASTing-like Approach in the Preoperative Setting: the BREAKFAST 2 Trial

Recruiting
2
145
Europe
Control diet (ARM A) or Fasting-Like Approach (FLA, ARM B)
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano, Istituto Oncologico Veneto IRCCS, Ospedale Policlinico San Martino, Federico II University, Azienda Policlinico Umberto I, European Institute of Oncology, Ospedale "Carlo Poma" - Mantova, Humanitas Clinical and Research Center
Breast Cancer, Triple Negative Breast Cancer, Dietary Exposure, Fasting
05/25
05/26
NCT06270602: The ONCOCAMP Study

Recruiting
N/A
15000
Europe
Data collection (retrospective), Data collection (prospective)
National Cancer Institute, Naples
Oncology
01/25
07/26
NCT05754502: Observational Study of Effectiveness and Safety of Trastuzumab Emtansine (T-DM1) in HER2-positive Breast Cancer Patients With Residual Invasive Disease Following Neoadjuvant Chemotherapy and Anti-HER2 Target Therapy

Recruiting
N/A
300
Europe
Trastuzumab emtansine
Consorzio Oncotech, Roche Pharma AG
Breast Cancer
09/24
05/25
PREFER-Fertility, NCT02895165: PREgnancy and FERtility Registry

Recruiting
N/A
1000
Europe
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy, Clinical Research Technology S.r.l.
Breast Neoplasms, Pregnancy, Fertility Preservation
11/27
11/32

Download Options